FDA Orders Eye-Risk Warnings for GLP-1 Drugs After Reports of Rare Vision Loss

The U.S. Food and Drug Administration is requiring warning-label updates for GLP-1 medicines, including Ozempic, Wegovy, Mounjaro and Zepbound. The update highlights a possible increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, painless vision loss in one eye and may lead to permanent blindness. The FDA says cases have been reported among people taking currently marketed GLP-1 medicines. NAION is also associated with factors such as diabetes, smoking, high blood pressure and high cholesterol. There is currently no treatment that can reverse vision loss caused by the condition.

Use The App To Win ₦1m

Stories are shared by community members. This article does not represent the official view of NaijaWorld — the author is solely responsible for its content.